Louisiana Wins Partial Victory in Mifepristone FDA Lawsuit — Family Research Council

Event summary

Judge David Joseph ruled Louisiana has standing to sue FDA over mifepristone regulations, finding pre-2023 REMS likely unlawful.
Court granted FDA six months to review safety but warned stay is not open-ended.
FRC's amicus brief cited 118,338 abortion drug packs mailed without in-person medical consultation between July 2023-September 2024.
Family Research Council supports Louisiana's appeal to 5th Circuit Court of Appeals.

The big picture

This ruling highlights the ongoing tension between state and federal authorities over abortion regulations, particularly concerning medication access. The case underscores how judicial appointments and administrative reviews can shape healthcare policy, with potential implications for other states seeking to challenge federal drug regulations. The strategic anomaly here is the court's willingness to acknowledge state harm while deferring to FDA's review process, creating a high-stakes timeline for regulatory action.

What we're watching

Regulatory Compliance: Whether FDA can complete its review within six months and address Louisiana's concerns about drug safety.
Legal Strategy: How the 5th Circuit Court of Appeals will handle Louisiana's appeal and whether it will uphold the lower court's findings.
Policy Impact: The pace at which states with restrictive abortion laws challenge federal drug regulations and the broader implications for healthcare policy.